Cargando…
The DNA60IFX contest
Autores principales: | Schatz, Michael C, Taylor, James, Schelhorn, Sven-Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706964/ https://www.ncbi.nlm.nih.gov/pubmed/23809492 http://dx.doi.org/10.1186/gb-2013-14-6-124 |
Ejemplares similares
-
Infliximab (IFX)-Biosimilar Induced Drug-Induced Liver Injury (DILI): A Case Report
por: Zachou, Maria, et al.
Publicado: (2022) -
Computational thinking in the era of big data biology
por: Schatz, Michael C
Publicado: (2012) -
Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54–78 Data From a Randomized, Double-Blind, Phase III Trial
por: Cohen, Stanley B., et al.
Publicado: (2020) -
Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response
por: Francica, Paola, et al.
Publicado: (2018) -
Discontinuation of biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving sustained clinical remission or low disease activity during the IFX-SIRIUS STUDY I (the IFX-SIRIUS STUDY II): Study protocol for an interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments
por: Shimizu, Toshimasa, et al.
Publicado: (2020)